Genomic sequencing analysis of 733 HER2-amplified Principal and metastatic breast tumours revealed sizeable enrichment of mutations that activate RAS–MAPK signalling in advanced tumours treated with prior anti-HER2 therapies121. These mutations, like NF1 and HER2 activating mutations, lead to resistance to tucatinib and neratinib. Expressing your thoughts. Obtain an action that https://www.directivepublications.org/journal-of-clinical-breast-cancer/